New endometrial immune cell-based score (EI-score) for the prediction of implantation success for patients undergoing IVF/ICSI

Lianghui Diao,Songchen Cai,Chunyu Huang,Longfei Li,Shuyi Yu,Linlin Wang,Su Liu,Yuye Li,Yong Zeng
DOI: https://doi.org/10.1016/j.placenta.2020.07.025
IF: 3.287
2020-09-01
Placenta
Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Problem</h3><p>Limited evidence revealed whether endometrial immune factors contribute to implantation success in the first-attempted in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) patients.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Method</h3><p>of Study: The retrospective study was conducted among 139 and 29 eligible couples in the deviation and validation cohorts, respectively. The expression of endometrial immune cell markers, including CD56 for natural killer cell, CD68 for pan-macrophage, CD163 for M2 macrophage, FOXP3 for regulatory T cell, CD1a for immature dendritic cell, CD83 for mature dendritic cell, CD8 for cytotoxic T cell and CD57 for mature NK and T cells were examined.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>The profiles of endometrial immune cells showed significantly different between the pregnant and implantation failure group in the derivation cohort. Multivariate logistic regression analysis showed that the percentage of CD68<sup>+</sup> pan-macrophage and CD163<sup>+</sup> M2-macrophage, as well as the transfer strategy are associated with implantation outcomes (<em>P</em> &lt; 0.001, <em>P</em> = 0.029, <em>P</em> = 0.004, respectively). The EI-score was constructed by a nomogram and validated by a clinical decision curve based on CD68<sup>+</sup> pan-macrophage, CD163<sup>+</sup> M2-macrophage, and the transfer strategy. The performance of the EI-score in the deviation cohort showed a c-index of 0.82 (95% CI 0.74–0.89), and the accuracy rate reached 79.3% in the validation cohort.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p>We introduced a novel model to aid in clinical decisions making for the IVF/ICSI patients, which may also shed light on the evaluation of endometrial receptivity. However, the quality control of the digital pathologic immune profiling should be ensured, and randomized studies should be conducted in multiple prospective research centers.</p>
obstetrics & gynecology,reproductive biology,developmental biology
What problem does this paper attempt to address?